Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections

被引:123
|
作者
Thangamani, Shankar [1 ]
Younis, Waleed [1 ]
Seleem, Mohamed N. [1 ]
机构
[1] Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
关键词
CA-MRSA SKIN; IN-VITRO; AUREUS; ANTIBIOTICS; INFLAMMATION; ANTIOXIDANT; EXPRESSION; SUSCEPTIBILITY; CHOLESTEROL; INHIBITION;
D O I
10.1038/srep11596
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Novel antimicrobials and new approaches to developing them are urgently needed. Repurposing already-approved drugs with well-characterized toxicology and pharmacology is a novel way to reduce the time, cost, and risk associated with antibiotic innovation. Ebselen, an organoselenium compound, is known to be clinically safe and has a well-known pharmacology profile. It has shown potent bactericidal activity against multidrug-resistant clinical isolates of staphylococcus aureus, including methicillin- and vancomycin-resistant S. aureus (MRSA and VRSA). We demonstrated that ebselen acts through inhibition of protein synthesis and subsequently inhibited toxin production in MRSA. Additionally, ebselen was remarkably active and significantly reduced established staphylococcal biofilms. The therapeutic efficacy of ebselen was evaluated in a mouse model of staphylococcal skin infections. Ebselen 1% and 2% significantly reduced the bacterial load and the levels of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), and monocyte chemo attractant protein-1 (MCP-1) in MRSA USA300 skin lesions. Furthermore, it acts synergistically with traditional antimicrobials. This study provides evidence that ebselen has great potential for topical treatment of MRSA skin infections and lays the foundation for further analysis and development of ebselen as a potential treatment for multidrug-resistant staphylococcal infections.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Treatment of pediatric Gram-positive multidrug-resistant infections
    Blumer, Jeffrey
    JOURNAL OF INFECTION, 2009, 59 : S51 - S58
  • [22] Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
    Karageorgopoulos, Drosos E.
    Falagas, Matthew E.
    LANCET INFECTIOUS DISEASES, 2008, 8 (12): : 751 - 762
  • [23] Treatment challenges: Multidrug-resistant tuberculosis and atypical mycobacteria infections
    Yew, WW
    PROCEEDINGS OF THE 8TH CONGRESS OF THE ASIAN PACIFIC SOCIETY OF RESPIROLOGY, 2003, : 103 - 105
  • [24] Treatment of Multidrug-Resistant Bacterial Infections Using Quantum Dots
    McCollum, Colleen
    Bertram, John
    Nagpal, Prashant
    Chatterjee, Anushree
    FASEB JOURNAL, 2022, 36
  • [25] A Review of Intravenous Minocycline for Treatment of Multidrug-Resistant Acinetobacter Infections
    Ritchie, David J.
    Garavaglia-Wilson, Alexandria
    CLINICAL INFECTIOUS DISEASES, 2014, 59 : S374 - S380
  • [26] Treatment of Multidrug-Resistant Gram-Negative Infections in Children
    Hsu, Alice J.
    Tamma, Pranita D.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (10) : 1439 - 1448
  • [27] MULTIDRUG-RESISTANT NONTYPHOIDAL SALMONELLA INFECTIONS
    UDGAONKAR, US
    KULKARNI, RD
    KULKARNI, VA
    DHARMADHIKARI, CA
    PAWAR, SG
    PARICHARAK, SD
    TROPICAL DOCTOR, 1995, 25 (03) : 104 - 106
  • [28] Multidrug-resistant Salmonella and nosocomial infections
    Dargatz, DA
    Traub-Dargatz, JL
    VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE, 2004, 20 (03) : 587 - +
  • [29] Management of Multidrug-Resistant Infections in Cirrhosis
    Gallaher, Charles E.
    Shawcross, Debbie L.
    SEMINARS IN LIVER DISEASE, 2022, 42 (02) : 173 - 187
  • [30] Management of multidrug-resistant enterococcal infections
    Arias, C. A.
    Contreras, G. A.
    Murray, B. E.
    CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (06) : 555 - 562